First Week Of February 2016 Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics ( NKTR) saw new options begin trading this week, for the February 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new February 2016 contracts and identified one put and one call contract of particular interest.

The put contract at the $12.00 strike price has a current bid of $1.40. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $12.00, but will also collect the premium, putting the cost basis of the shares at $10.60 (before broker commissions). To an investor already interested in purchasing shares of NKTR, that could represent an attractive alternative to paying $12.45/share today.

Because the $12.00 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 11.67% return on the cash commitment, or 17.67% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Nektar Therapeutics, and highlighting in green where the $12.00 strike is located relative to that history:

If you liked this article you might like

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

Biotech Movers: NeuroDerm Shares Soar on Sale to Japanese Firm

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Nektar Shares Boosted by Promising Results on Opioid Addiction Study

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct